TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06240676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARENESS-BASED COGNITIVE THERAPY
Description: A 6-week training program based on mindfulness practices will be applied to the experimental group determined by the single-blind method, after the 3rd month after birth. In order to observe the change in the experimental group, breast milk will be taken for pre-test (morning and evening) before training. After 6 weeks of training, a cortisol test will be performed by taking breast milk at 09:00 in the morning and 09:00 in the evening. Taken milk will be stored in the deep freezer for 1 week at -18 degrees. After the samples are prepared for testing under appropriate conditions (centrifuge), biochemical measurements will be made and recorded with the help of the SUNREDBIO brand human cortisol kit (the serial number is not known since we did not purchase the cortisol kit).A sleep diary will be used to measure newborn circadian rhythm.
Study: NCT05892900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS)
Description: The electrodes are placed at the left ear concha. The ear concha is principally innerved by the afferent branch of the vagus nerve

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous vagus nerve stimulation (Sham tVNS)
Description: The electrodes are attached to the center of the left ear lobe, which is known to be free of cutaneous vagal innervation
Study: NCT06456892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pucotenlimab
Description: Pucotenlimab Combined with Standard Chemotherapy Regimen
Study: NCT05935137

Intervention type: DIAGNOSTIC_TEST
Intervention: Coagulation test on device ClotPro
Description: The blood sample for coagulation test on device ClotPro will be take for both group and the test will be provided.
Study: NCT04211181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The multifaceted interventions
Description: 1. An evidence-based clinical guideline and pathway in hospital.~2. A series Written care protocols for the implementation of performance measures.~3. A computer-based clinical decision support system(CDSSs) and a computerized reminder, which was referred to as a key element to enhance VTE assessment and prophylaxis. A well-designed computer program will be integrated into the Electronic Medical Record(EMR) of intervention group and By processing, analyzing, summarizing and representing crucial information, physicians can be altered.~4. A full-time quality coordinator~5. A trained physician or nurse in each intervention cluster will be acted as a quality coordinator. The responsibility of the quality coordinator includes:

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine VTE prophylaxis
Description: Patients randomized to the Routine VTE prophylaxis (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices
Study: NCT05379777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remimazolam The starting dose of remimazolam is 1 mg/kg/hr. If sedation does not proceed successfully, increase the infusion rate by 0.2 mg/kg/hr in the next patient. (However, if the infusion rate is less than 0.6mg/kg/hr, the dose is increased by 0.1mg/kg/hr.) If sedation has progressed successfully until the end of surgery, the next patient will use the same dose with a probability of 0.89 or 0.11 It is reduced by 0.2 mg/kg/hr with a probability of (However, if the infusion rate is 0.6mg/kg/hr or less, reduce it by 0.1mg/kg/hr.)
Study: NCT05471297

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no any intervention
Study: NCT06327438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex decongestive therapy
Description: 1. Manual lymphatic drainage (MLD).~2. Compression bandage.~3. Exercises to enhance lymphatic drainage.~4. Skin care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex decongestive therapy
Description: 1. Manual lymphatic drainage (MLD).~2. Compression bandage.~3. Exercises to enhance lymphatic drainage.~4. Skin care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex decongestive therapy
Description: 1. Manual lymphatic drainage (MLD).~2. Compression bandage.~3. Exercises to enhance lymphatic drainage.~4. Skin care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: It is a mature and safe-to-use system that cools the air to -32°C. Steps of application included: 1) Apply oil or cream to moisture the skin before cryotherapy application; 2) Initialize the mini cryo-air equipment at level 6.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: It is a new choice in the field of physical therapy. The material used for the KT and the original concept of the taping technique were introduced by Dr Kenso Kase in 1973.
Study: NCT05586295

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline α-cellulose, shellac, calcium hydrogen phosphate, edible yellow No. 4, edible yellow No. 5, sucrose, silica, talc, oxidized starch, gelatin, magnesium stearate, palm wax.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EX plus
Description: Furanthiamine hydrochloride (vitamin B1), pyridoxine hydrochloride (vitamin B6), cyanocobalamin (vitamin B12), DL-alpha-tocopheryl acetate 50% (DL-alpha-tocopheryl acetate, sucrose, caprylic acid) Sodium alkenyl succinate starch, corn starch, water, sodium aluminosilicate), shellac, calcium hydrogen phosphate, edible yellow No. 4, edible yellow No. 5, γ-oryzanol (γ-oryzanol, rice bran powder ), sucrose, silica, inositol, taurine, talc, oxidized starch, gelatin, magnesium stearate, calcium panpolyate, microcrystalline α-cellulose, riboflavin (vitamin B2), palmar wax.
Study: NCT05769036

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Biventricular Pacing
Description: The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation of the left ventricular pacing lead will be performed by cannulating one of the tributaries of the coronary sinus using delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed for biventricular pacing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Left Bundle Branch Pacing
Description: The local anesthesia will be performed on the left/right subclavian area after prepping the skin. A horizontal incision will be performed. The cephalic and subclavian veins will be used to leads deliver. The active-fixation defibrillation lead will be placed to the apex/interventricular septum. The atrial active-fixation lead will be implanted to the right atrial appendage/interatrial septum. The implantation to the left bundle branch will be performed by using special delivery system. Leads will be fixated, connected with CRT-D device and placed in subcutaneous (subfascial prepectoral)/submuscular pocket. The pocket will be closed by separate stitches (2-4 suffice) using the resorbable braided suture. Cardioverter-defibrillator with a resynchronization function will be programmed left bundle branch pacing.
Study: NCT05901454

Intervention type: DRUG
Group type: OTHER
Intervention: Yellow Fever Vaccine
Description: vaccination according to manufacturers manual (0.5mL subcutaneously in the arm)
Study: NCT05539547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Nerve Stimulation
Description: Application of NMES on quadriceps muscle groups bilaterally~Frequency: \>50Hz Pulse duration: 350 - 400µs Intensity: Maximal tolerance (visible quadriceps muscle contraction and/or maximally tolerated by the patient, eliciting a slight discomfort) Time: 30 minutes per session, 7 sessions per week Duty Cycle: 2s on / 18s off Duration: Until discharge to a maximum of 30 days

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Physiotherapy treatment (Chest Physiotherapy and mobility)
Description: Daily chest physiotherapy and mobility
Study: NCT05089916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib: according to its marketing authorization, i.e. at daily doses of 80 mg, for a maximum of 12 months within the study.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy: according to standard of care~The target population will comprise 3 parallel cohorts, for cohort 1 and 3 a minimum of 10 subjects is planned to be enrolled:~1. Irradiation of bone, solid organ (non-lung, non-brain) or soft-tissue metastases~2. Irradiation of brain metastases (initial lesion size \< 3 cm)~3. Irradiation of lung lesions (primary tumor or metastases, lesion size \< 5 cm)
Study: NCT06528080

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LY-M001
Description: LY-M001 Injection by Single Intravenous Infusion
Study: NCT04826302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial treatment
Description: 40 minutes of myofascial intervention: 10 min in each of the following regions with the patient face up:~* Thoracolumbar fascia and abdomen~* C7-T4 and sternum~* Suboccipital area~* Temporary area

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham myofascial treatment
Description: 40 minutes of sham myofascial intervention: 10 min in each of the following regions with the patient face up and with the contact of the physiotherapist through a towel and without any intention:~* Thoracolumbar fascia and abdomen~* C7-T4 and sternum~* Suboccipital area~* Temporary area
Study: NCT06465238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009
Description: Treatment group: Subjects will receive an intravenous infusion of SHR-A2009 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Study: NCT05034952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB/APAP
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-548)
Description: Placebo matched to VX-548 for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.
Study: NCT06634498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real rTMS on the dlPFC
Description: During real rTM session, participants will perform the regulation of craving (ROC). In the rest phase, participants need to relax and rest. In the ROC task, participants will regulate craving elicited by gaming pictures using cognitive reappraisal. During the task, reaction times (RTs) and craving scores wil be recorded.
Study: NCT06454435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel
Description: Drug: Sintilimab Sintilimab 200mg, D1, IV, Q3W 4-8 cycles Drug: Fruquintinib Fruquinitinib 4mg/d, QD, PO, D1-D14, Q3W 4-8 cycles Drug: S-1 BSA\<1.25 m2, 40mg twice/day; BSA 1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, D1-D14, Q3W 4-8 cycles Drug: Nab-paclitaxel~* without peritoneal metastases: 260 mg/m2, IV, D1 for 3h, Q3W 4-8 cycles;~* with peritoneal metastases: 80mg/m2 IP, plus 180mg/m2, IV, D1, Q3W 4-8 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab + S-1 plus nab-paclitaxel
Description: Drug: Sintilimab Sintilimab 200mg, D1, IV, Q3W 4-8 cycles Drug: S-1 BSA\<1.25 m2, 40mg twice/day; BSA 1.25-1.5m2, 50mg twice/day; BSA≥1.5 m2, 60mg twice/day, po, D1-D14, Q3W 4-8 cycles Drug: Nab-paclitaxel~* without peritoneal metastases: 260 mg/m2, IV, D1 for 3h, Q3W 4-8 cycles;~* with peritoneal metastases: 80mg/m2 IP, plus 180mg/m2, IV, D1, Q3W 4-8 cycles.
Study: NCT06634498

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: During the sham rTMS session, participants will perform the regulation of craving (ROC). In the ROC task, participants will regulate craving elicited by gaming pictures using cognitive reappraisal. During the task, reaction times (RTs) and craving scores wil be recorded.
Study: NCT05765721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FRAIL-SM Program
Description: Patients in experimental group will receive a 8 week family-based frailty self-management program; patients in control group maintain their usual life activities.
Study: NCT06495606

Intervention type: DIAGNOSTIC_TEST
Intervention: Voice sample; Recording with microphone + Questionnaire
Description: Voice sample recording with microphone; afterwards digitalization and comparison between GERD and Non-GERD Group and also between GERD-Group before and after GERD treatment; searching for vocal biomarkers typical for GERD

Intervention type: DIAGNOSTIC_TEST
Intervention: Voice sample; Recording with microphone + Questionnaire
Description: Voice sample recording with microphone; afterwards digitalization and comparison between GERD and Non-GERD Group and also between GERD-Group before and after GERD treatment; searching for vocal biomarkers typical for GERD
Study: NCT05950321

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paramedian cervical epidural steroid injection
Description: For paramedian cervical epidural steroid injection, the cervical 7 (C7) - thoracic 1 (T1) interval is determined by taking an appropriate angle with C-arm fluoroscopy to determine the interlaminar space from the posterior cervical region. The epidural space is recognized by the negative pressure reflected on the resistance syringe.
Study: NCT04957654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VST with collagen plug soaked in blood
Description: -A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with collagen plug soaked in blood

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VST with Allograft Demineralized bone matrix Grafton
Description: -A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with Allograft Demineralized bone matrix Grafton

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VST with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles
Description: -A sub mucoperiosteal tunnel will be created, a membrane shield will be trimmed to fit the facial wall of the socket and introduced through the tunnel lying over the facial bone plate, and the facial gap will be filled with a particulate bone graft composed of two thirds autogenous cortical chips harvested from the surgical site and one third of bovine deprotinzed particles
Study: NCT04697251

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FOT measurements in newborns and small infants
Description: Measurements will be performed using the device TremoFlo N-100, at bedside, with the infant in the supine position during quiet natural sleep. After proper cleaning and decontamination, the face mask of the device will be preheated at 37oC (to avoid awakening) and will be placed on infant's face. The duration of each measurement will be predetermined at 10 s. At least 3 technically acceptable measurements will be performed per infant, with 30 s intervals between them. The validity of each measurement will be assessed according to the coherence function (automatically determined by the operating system of the device).
Study: NCT05950321

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective nerve root pulsed radiofrequency
Description: For selective nerve root PRF, an 8-12 Hz linear ultrasound probe is first placed posterolateral to the neck. The level of the cervical nerve roots is determined according to the morphology of the anterior and posterior vertebral tubercles. The corresponding nerve root is visualized hypoechoically between the tubercles. The radiofrequency cannula is inserted in the same plane as the ultrasound probe (in plane) and the relevant nerve root is approached. Pulsed radiofrequency current, which has therapeutic properties in chronic pain, is applied to the relevant nerve root for 240 seconds.
Study: NCT05656508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)
Description: 2 doses of vaccine with an interval between doses of 28 days. Administration route: Intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARVAC-CG vaccine (recombinant protein vaccine against SARS-CoV-2)
Description: 2 doses of vaccine with an interval between doses of 28 days. Administration route: Intramuscular (IM) injection
Study: NCT05878067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-444
Description: Lubricant Eye drops
Study: NCT05508347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nituzumab/placebo
Description: Test group: 3 cycles of induction chemotherapy combined with 9 times of nituzumab targeted therapy followed by 2-3 cycles of synchronous radiotherapy and chemotherapy combined with 7 times of nituzumab targeted therapy, a total of 16 times of nituzumab targeted therapy, equivalent to the whole course targeted therapy.~Control group: 3 cycles of induction chemotherapy combined with 9 times of placebo treatment followed by 2-3 cycles of concurrent chemoradiotherapy combined with 7 times of nituzumab targeted therapy, a total of 7 times of nituzumab targeted therapy, only targeted therapy during concurrent chemoradiotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nituzumab/placebo
Description: Test group: 3 cycles of induction chemotherapy combined with 9 times of nituzumab targeted therapy followed by 2-3 cycles of synchronous radiotherapy and chemotherapy combined with 7 times of nituzumab targeted therapy, a total of 16 times of nituzumab targeted therapy, equivalent to the whole course targeted therapy.~Control group: 3 cycles of induction chemotherapy combined with 9 times of placebo treatment followed by 2-3 cycles of concurrent chemoradiotherapy combined with 7 times of nituzumab targeted therapy, a total of 7 times of nituzumab targeted therapy, only targeted therapy during concurrent chemoradiotherapy
Study: NCT04871607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetically Engineered Hematopoietic Stem Progenitor Cells
Description: Given via infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Granulocyte Colony-Stimulating Factor
Description: Given SC or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Basiliximab
Description: Given IV
Study: NCT05125367

Intervention type: PROCEDURE
Intervention: coronary stent implantation
Description: coronary stent implantation using everolimus-eluting balloon expandable stents
Study: NCT05367947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-phase Bilateral Exercises of the upper limbs
Description: The intervention protocol consists of in-phase bilateral exercises for the upper limbs, which are adapted to different sport activities and to fitness functional exercises, organized in a circuit training. Specifically, each session will consist of 1-3 sets, consisting of 10-15 repetitions of 9 different exercises targeting large muscle groups of the upper limbs.~The specific exercises will include sports activities of basic technical skills of basketball (e.g., different types of passing, catching and throwing the ball) and volleyball (e.g., different types of passing and receiving the ball), whereas the fitness exercises will include shoulder rows, shoulder lateral raises, elbow flexions, elbow extensions, using resistance elastic bands, as well as exercises with the patients' own body weight (e.g., pushups, TRX).~The intervention phase for each participant will consist of 12 consecutive weeks, for 3 times per week, 30-60 minutes each session.
Study: NCT06167148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biolase Epic X 940nm wavelength Diode laser
Description: Participants were treated with Biolase Epic X 940nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (P3).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Doctor smile simpler 980nm wavelength Diode laser
Description: Participants were treated with doctor smile simpler 980nm wavelength Diode laser set at a power of 1 W, fiber 400 µ, irradiation mode: pulsed wave (SP).
Study: NCT05125367

Intervention type: PROCEDURE
Intervention: bypass grafting
Description: coronary artery bypass graft